Cibus, Inc. (Nasdaq: CBUS) announced its financial results for the fourth quarter and year ended December 31, 2025, revealing a net loss of $31.9 million for the quarter, compared to a loss of $25.8 million in the same period last year. The company's cash position stood at $9.9 million as of December 31, 2025, with expectations that existing cash and cash equivalents will be sufficient to fund operations into late Q3 2026. The report highlighted a decrease in research and development expenses to $9.4 million from $12.4 million year-over-year, attributed to cost reduction initiatives. Selling, general, and administrative expenses also fell to $5.1 million from $6.8 million, reflecting ongoing efforts to streamline operations.

Cibus's leadership, led by Interim CEO Peter Beetham, emphasized the company's strategic advancements in gene editing technologies and the regulatory landscape, which has reached a critical inflection point with the EU's political agreement on New Genomic Techniques legislation. This development is expected to facilitate broader commercial acceptance of precision breeding technologies, positioning Cibus favorably in the market.

The company reported initial customer payments from its Sustainable Ingredients program, marking a significant milestone in its commercialization efforts. Cibus is also advancing its Rice program, with seven partner customers driving near-term commercial launch targets in the USA and Latin America, potentially generating over $200 million in annual royalties at peak.

Despite the increased losses, Cibus remains optimistic about its operational execution and strategic outlook, focusing on enhancing its technology leadership and expanding its market presence. The company plans to host a conference call to discuss these results and provide further insights into its business strategy moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.